Do excellent whilst earning profits: A guidebook to socially accountable investing
What is socially accountable investing?
Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Generally, socially responsible traders favor company practices that happen to be environmentally accountable, help workplace diversity and grow products security and excellent.
Harris James Associates New York, ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client’s success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
RI tactics supply investors using the opportunity to produce beneficial modify on the planet by their personal decisions whilst remaining concentrated on their long-term investment strategy.
Investing funds in a socially aware method has gained reputation given that the 1970s, while the origins of your idea is often traced again for the 17th century. The idea grew for any number of good reasons, including concerns with regards to the setting, purchaser and employee rights, and army actions.
Lots of individuals who had been civil rights and anti-war protestors in the 1960s grew to become traders inside 1970s and 1980s and had been searching for a way to express their convictions via their investment portfolios. The 1st mutual fund to display investments dependant on social criteria was established in 1971.
Right now, greater than 200 mutual money give investors a way to entry a social investment system. Some money are broad in nature, even though other individuals focus on a distinct bring about.
According to your Social Investment Forum, in 2007, just about one from each and every 9 dollars below qualified management within the U.s. (in excess of $2.71 trillion) was associated with socially accountable investing, outpacing the overall marketplace. Curiosity within this investment method has grown greatly given that the mid-1990s.
Alongside money and other professionally managed portfolios that specialize in socially accountable types, the Social Investment Forum studies that mainstream funds managers are also incorporating social and environmental screens into their investment choice processes. The strategy has also taken on world wide dimensions, as far more investors throughout the entire world find to promote specific leads to by way of their investment dollars.
Dienstag, 19. April 2011
Harris James Associates For New Investors: The Basics of IPO
Harris James Associates, New York is one of the market leader in Financial Services. The following serves as a guide to Initial Public Offering (IPOs) made to eliminate the fear (and simplify the jargon) that IPO’s are more risky than ordinary investments.
At HJA New York, we offer our clients with the most recent and widest choices of financial products and services. These days, we know that choosing the right investment, the right product and the right strategy is not a walk in the park. So whether it concerns investments, financial planning or advice, we are here to answer all your questions and assist in your financial needs.
Harris James Associates ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
Harris James Associates will also seek to provide expertise to investee companies not commonly available from institutional investors. In return, HJA expects to earn strategic investment grade entry prices by creating or securing investment opportunities that might not otherwise be available.
Making a private company public is done through an Initial Public Offering (IPO). This phase is definitely one of the most crucial moments in a company’s timeline. The company issues a certain number of share certificates at a fixed price. Each share can be bought or sold on the stock market where the company is listed, and each stockholder in turn becomes part owner of the company.
It’s a particularly complex process with a maze of compliance and regulatory requirements. But the financial benefits are just as great. A well-subscribed and successful IPO can turn a small company into an international corporate heavyweight at once.
The greatest advantage of a public offering is undeniably the massive capital infusion to fund the ongoing operations and planned expansion of the company. It can reduce the company’s debt and significantly improves its liquidity position. Also, there’s a big uptick in brand recognition and trust in the company’s services and products.
First, a prospectus for the IPO and a registration statement are filed with the SEC. It details everything an investor would like to know about the company and its plans in the future. This is where the underwriters come into the picture.
Underwriters not only assist with the filing requirements but also alter the company’s structure, meaning, they help in the transition of the company into a private enterprise into a public one (with stockholders and a Board). However, their primary job is to aid in deciding on the specifics of the IPO like the number of shares, the pricing and the market.
When the public offering pass, the company has specific new responsibilities that include making public the quarterly financial results, filing statements with the SEC for anything major the affects the company and its operations, and the AGM. At a stockholders’ meeting, essential concerns are discussed and voted upon, including the composition of top-level management and the Board. This is why after an IPO, most companies hire new managers: to deal with certain issues of public companies.
The success of an IPO primarily depends on the growth potential of the company and the sector where it belongs, and if the business has fine basics and revenue model. However, many IPO’s failed despite of having all that. Maybe, it is because they did not select the right price or the right market, or simply pick the wrong time to go public.
Take Canada for example, where an IPO won’t be able to get to the price or size that an offering in the US markets can fetch. The market in Canada has a lower risk threshold. And in Europe, there are more concerns that need to be addressed, such as the condition of the economy in each member’s state of the EU that affect every market in Europe.
Back when dotcoms were still in trend, practically anyone with a website could file for an IPO, and watch the millions pile up as the markets steadily rise. But now, what investors want is a safe company with long term growth prospects and lots of assets to its name. For any business that can pass through this long road to IPO success, there’s a great prize on the other end.
At HJA New York, we offer our clients with the most recent and widest choices of financial products and services. These days, we know that choosing the right investment, the right product and the right strategy is not a walk in the park. So whether it concerns investments, financial planning or advice, we are here to answer all your questions and assist in your financial needs.
Harris James Associates ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
Harris James Associates will also seek to provide expertise to investee companies not commonly available from institutional investors. In return, HJA expects to earn strategic investment grade entry prices by creating or securing investment opportunities that might not otherwise be available.
Making a private company public is done through an Initial Public Offering (IPO). This phase is definitely one of the most crucial moments in a company’s timeline. The company issues a certain number of share certificates at a fixed price. Each share can be bought or sold on the stock market where the company is listed, and each stockholder in turn becomes part owner of the company.
It’s a particularly complex process with a maze of compliance and regulatory requirements. But the financial benefits are just as great. A well-subscribed and successful IPO can turn a small company into an international corporate heavyweight at once.
The greatest advantage of a public offering is undeniably the massive capital infusion to fund the ongoing operations and planned expansion of the company. It can reduce the company’s debt and significantly improves its liquidity position. Also, there’s a big uptick in brand recognition and trust in the company’s services and products.
First, a prospectus for the IPO and a registration statement are filed with the SEC. It details everything an investor would like to know about the company and its plans in the future. This is where the underwriters come into the picture.
Underwriters not only assist with the filing requirements but also alter the company’s structure, meaning, they help in the transition of the company into a private enterprise into a public one (with stockholders and a Board). However, their primary job is to aid in deciding on the specifics of the IPO like the number of shares, the pricing and the market.
When the public offering pass, the company has specific new responsibilities that include making public the quarterly financial results, filing statements with the SEC for anything major the affects the company and its operations, and the AGM. At a stockholders’ meeting, essential concerns are discussed and voted upon, including the composition of top-level management and the Board. This is why after an IPO, most companies hire new managers: to deal with certain issues of public companies.
The success of an IPO primarily depends on the growth potential of the company and the sector where it belongs, and if the business has fine basics and revenue model. However, many IPO’s failed despite of having all that. Maybe, it is because they did not select the right price or the right market, or simply pick the wrong time to go public.
Take Canada for example, where an IPO won’t be able to get to the price or size that an offering in the US markets can fetch. The market in Canada has a lower risk threshold. And in Europe, there are more concerns that need to be addressed, such as the condition of the economy in each member’s state of the EU that affect every market in Europe.
Back when dotcoms were still in trend, practically anyone with a website could file for an IPO, and watch the millions pile up as the markets steadily rise. But now, what investors want is a safe company with long term growth prospects and lots of assets to its name. For any business that can pass through this long road to IPO success, there’s a great prize on the other end.
JAMES HARRIS ASSOCIATES INC.
Listed below are a number of articles related to pharmaceutical and biotechnology operations. Also listed are numerous FDA regulations and regulatory guidance documents. In all cases, these documents may be accessed directly by double clicking on the underlined hypertext listing.
Many of these documents are available in Adobe Portable Document Format (PDF). Articles in PDF are identified as such in their description. To read these documents, you much have Adobe Acrobat or Adobe Acrobat Reader. If you do not already have Adove Acrobat Reader available on your computer, it may be downloaded at no cost directly from Adobe. To download Adobe Acrobat Reader, double-click here.
This listing is constantly being upgraded, so check it regularly to keep current with changing regulations and technologies.
To access a document, double-click anywhere in the title for the desired listing.
Current Good Manufacturing Practice for Finished Pharmaceuticals. (This is the current regulation)
Manufacture, Processing or Holding Active Pharmaceutical Ingredients. This Guidance document is listed as a draft document. On a practical basis, however, it is the current GMP regulation for the manufacture and holding of Bulk Pharmaceutical Ingredients. Released 20 September, 1996. (PDF)
Final Rules on the Use of Electronic Signatures. According to FDA, these rules, which apply to all FDA program areas, are intended to permit the widest possible use of electronic technology compatible with FDA's responsibility to promote and protect public health. The use of electronic records is voluntary. (PDF)
Proposed Revisions to cGMP Regulations for Finished Dosage Forms. Proposed changes to the cGMP regulations for the purposes of clarification. Published in the Federal Register in May, 1996. Following a comment period, it is assumed that this will become the current GMP regulation. (PDF)
Guideline on General Principles of Process Validation. Published in May of 1987, this document is extremely out of date, but remains the published standard. The new validation section in the proposed GMPs provides better guidance.
Guidance for Industry: Immediate Release Solid Oral Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing, and In-Vivo Bioequivalence Documentation. Known as SUPAC-IR, this document provides guidance regarding the types of documentation needed to substantiate any formulation or process change following the clinical trial batches. (PDF)
Guidance for Industry: Manufacturing Equipment Addendum to Guidance for Industry For Scale-up and Post Approval Changes for Immediate Release Solid Oral Dosage Forms. This is the equipment companion to the SUPAC-IR document listed above. (PDF)
SUPAC-MR: Modified Release Solid Oral Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing and In-Vivo Bioequivalence Documentation. This is the same as SUPAC-IR except covering solid dosage forms that are formulated for modified release. (PDF)
SUPAC-SS: Nonsterile Semisolid Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing, and In-Vivo Bioequivalence Documentation. One more entry in the SUPAC series - this time for non-sterile semisolids. (PDF)
Computerized Systems Used in Clinical Trials. This is a draft document and does not have official standing. It is still a reflection of FDAs thinking. (PDF)
Submission of Documentation in Drug Applications for Container Closure Systems Used in Packaging of Human Drugs and Biologics. FDA has found that container closure systems play a major role in product stability. This guidance document deals with the information about container closure systems that must be submitted when applying for permission to sell a drug product in the U.S. (PDF)
Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products. This document is somewhat unique because it is one of the few guidance documents from CBER. (PDF)
Guidance for the Industry for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Vetinary Products. The title of this document tells it all. A must if you are validating sterilization processes or submitting NDAs for sterile products. (PDF)
Guideline for Submitting Documentation for Packaging for Human Drugs and Biologics.
Guidline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Product.
Guidline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Similar to the Guideline for Drug Product except that this Guidance Document applies to bulk manufacture. (PDF)
Many of these documents are available in Adobe Portable Document Format (PDF). Articles in PDF are identified as such in their description. To read these documents, you much have Adobe Acrobat or Adobe Acrobat Reader. If you do not already have Adove Acrobat Reader available on your computer, it may be downloaded at no cost directly from Adobe. To download Adobe Acrobat Reader, double-click here.
This listing is constantly being upgraded, so check it regularly to keep current with changing regulations and technologies.
To access a document, double-click anywhere in the title for the desired listing.
Current Good Manufacturing Practice for Finished Pharmaceuticals. (This is the current regulation)
Manufacture, Processing or Holding Active Pharmaceutical Ingredients. This Guidance document is listed as a draft document. On a practical basis, however, it is the current GMP regulation for the manufacture and holding of Bulk Pharmaceutical Ingredients. Released 20 September, 1996. (PDF)
Final Rules on the Use of Electronic Signatures. According to FDA, these rules, which apply to all FDA program areas, are intended to permit the widest possible use of electronic technology compatible with FDA's responsibility to promote and protect public health. The use of electronic records is voluntary. (PDF)
Proposed Revisions to cGMP Regulations for Finished Dosage Forms. Proposed changes to the cGMP regulations for the purposes of clarification. Published in the Federal Register in May, 1996. Following a comment period, it is assumed that this will become the current GMP regulation. (PDF)
Guideline on General Principles of Process Validation. Published in May of 1987, this document is extremely out of date, but remains the published standard. The new validation section in the proposed GMPs provides better guidance.
Guidance for Industry: Immediate Release Solid Oral Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing, and In-Vivo Bioequivalence Documentation. Known as SUPAC-IR, this document provides guidance regarding the types of documentation needed to substantiate any formulation or process change following the clinical trial batches. (PDF)
Guidance for Industry: Manufacturing Equipment Addendum to Guidance for Industry For Scale-up and Post Approval Changes for Immediate Release Solid Oral Dosage Forms. This is the equipment companion to the SUPAC-IR document listed above. (PDF)
SUPAC-MR: Modified Release Solid Oral Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing and In-Vivo Bioequivalence Documentation. This is the same as SUPAC-IR except covering solid dosage forms that are formulated for modified release. (PDF)
SUPAC-SS: Nonsterile Semisolid Dosage Forms - Scale-up and Post Approval Changes: Chemistry, Manufacturing and Controls, In-Vitro Dissolution Testing, and In-Vivo Bioequivalence Documentation. One more entry in the SUPAC series - this time for non-sterile semisolids. (PDF)
Computerized Systems Used in Clinical Trials. This is a draft document and does not have official standing. It is still a reflection of FDAs thinking. (PDF)
Submission of Documentation in Drug Applications for Container Closure Systems Used in Packaging of Human Drugs and Biologics. FDA has found that container closure systems play a major role in product stability. This guidance document deals with the information about container closure systems that must be submitted when applying for permission to sell a drug product in the U.S. (PDF)
Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products. This document is somewhat unique because it is one of the few guidance documents from CBER. (PDF)
Guidance for the Industry for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Vetinary Products. The title of this document tells it all. A must if you are validating sterilization processes or submitting NDAs for sterile products. (PDF)
Guideline for Submitting Documentation for Packaging for Human Drugs and Biologics.
Guidline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Product.
Guidline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Similar to the Guideline for Drug Product except that this Guidance Document applies to bulk manufacture. (PDF)
Abonnieren
Posts (Atom)